Showing results (121-130 of 233) with videos related to

Sort By:
Pageof 24
Blood Cancer Journal|March 31, 2026
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patientsHira Cheema, Asis Shrestha, Syed Naqvi, et al.
Haematologica|June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataSarah Waheed, Alan Mitchell, Saad Usmani, et al.
Blood|June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSaad Z Usmani, Rachel Sexton, Antje Hoering, et al.
British Journal of Haematology|May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Current Problems in Cancer. Case Reports|March 16, 2026
Breast-implant associated unicentric castleman disease: a case reportSaishravan Shyamsundar, Mateo Sarmiento Bustamante, Larissa Borys, et al.
Haematologica|May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaXenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
American Journal of Hematology|June 20, 2025
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning AnalysisMidori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, et al.
European Journal of Haematology|October 27, 2020
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNAShayu Deshpande, Ruslana G Tytarenko, Yan Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2010
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2Yiming Zhou, Lijuan Chen, Bart Barlogie, et al.
Pageof 24